DBV Technologies S.A. - American Depositary Shares - fluxo de caixa (NASDAQ:DBVT)

Financials

Fluxo de caixa operacional -165.61 M-108.24 M-55.67 M-79.65 M-104.47 M-121.18 M -150.58 M Fluxo de caixa de investimento -2.87 M-433 K-100 K-808 K-757 K-1.37 M -1.27 M Fluxo de caixa de financiamento 149.55 M274 K194.12 M6.77 M587 K276.18 M 365.08 M Fluxo de caixa livre -165.61 M-108.24 M-55.67 M-79.65 M-104.47 M-121.18 M -150.58 M

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

DBVT

Financials

DBV Technologies S.A. - American Depositary Shares

Notícias

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know

DBV Technologies: A Tough Nut To Crack In A Shrinking Market (NASDAQ:DBVT)

Cantor Fitzgerald reitera classificação da ação da DBV Technologies devido ao potencial do adesivo

Cantor Fitzgerald reitera classificação acima da média para ações da DBV Technologies

Citizens eleva preço-alvo da DBV Technologies com base em perspectivas de medicamento para alergia

Citizens reitera recomendação sobre ações da DBV Technologies pelo potencial do Viaskin Peanut

Citizens reiterates DBV Technologies stock rating on Viaskin Peanut potential

Ações da DBV Technologies disparam com novos dados de teste de adesivo para alergia a amendoim

DBV Technologies stock surges on new peanut patch trial data